Evaluation of the Performance of MAgnetic Gastrointestinal Universal Septotome for Treatment of Candy Cane Syndrome

NCT ID: NCT05938439

Last Updated: 2023-11-18

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

51 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-08-01

Study Completion Date

2027-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Candy cane syndrome (CCS) is an adverse event (AE) from gastrectomy or gastric bypass and end-to-side anastomosis to a jejunal loop. It seems to be predominantly mechanical, the afferent blind loop enlarge and becomes preferential passage of food. This food accumulated in the blind loop increase luminal pressure, causing dilatation, early satiety, fullness, pain, reflux, regurgitation, postprandial vomiting, weight loss, and, ultimately, inability to eat, leading to cachexia.Up to now, main treatment is laparoscopic revision which is invasive. Adverse events related this surgical procedure occurred in 13,3% of cases and substantial improvement only in 73.9%.

A first clinical study with MAGUS including oesophageal diverticulum (n=2) and CCS (n=14) has been performed to assess safety and feasibility of this new device. MAGUS is an implantable device which is placed endoscopically and which, by using pressure necrosis, entailed the marsupialization of the blind loop in less than 30 days. Substantial improvement was observed in all patient and only 7,1% of patients experience an adverse event possibly related to the device. This study aim therefore to assess the safety and performance of the endoscopic treatment of CCS using a new medical device: MAGUS.

This will be a single-center, open-label prospective, safety and performance study on 51 patients with Candy Cane Syndrome (CCS). Patients will be followed for 12 months after the procedure, with an enrolment period of 3 years.

After the screening, the following data will be collected and examinations and tests performed : physical Exam, medical history including CCS cause and treatment(s) history, weight, Eckart and dysphagia score, Quality of Life questionnaire (SF 12 and GERD HRQL), Main symptom selection (Nausea, Vomiting/regurgitation or pain), nausea VAS, vomiting, regurgitation VAS, pain VAS, barium swallow X-ray or endoscopic assessment of Candy Cane. Follow-up visits will be performed at 14 days, 28 days, 3 months and 12 months post-procedure.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Blind Loop Syndrome Postoperative Candy Cane Syndrome

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Interventional

The procedure consists in Medical Device (MAGUS) placement by endoscopy under general anesthesia with fluoroscopic control.

Group Type EXPERIMENTAL

MAGUS placement

Intervention Type DEVICE

An upper endoscopy will be performed with the use of fluoroscopy under general anaesthesia with orotracheal intubation. The delivery system will be placed over a guidewire, under fluoroscopy. The main steps are the following:

* Placement through the endoscope of a soft guidewire through the upper GI tract;
* Insertion of the MAGUS system on the guidewire;
* Advancement of the MAGUS system until proximal magnet reach the top of the septum;
* Release and placement of the proximal magnet at the bottom of the septum, pouch side;
* Meeting of the distal and proximal magnet on both sides of the septum, by pulling on the delivery system;
* Release of the distal magnet and activate the retractable wire;
* Insure that wire is not blocked and unblocked it if applicable.

Endoscopy and contrast injection will be performed before and after placement to ensure the correct positioning of the magnets.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

MAGUS placement

An upper endoscopy will be performed with the use of fluoroscopy under general anaesthesia with orotracheal intubation. The delivery system will be placed over a guidewire, under fluoroscopy. The main steps are the following:

* Placement through the endoscope of a soft guidewire through the upper GI tract;
* Insertion of the MAGUS system on the guidewire;
* Advancement of the MAGUS system until proximal magnet reach the top of the septum;
* Release and placement of the proximal magnet at the bottom of the septum, pouch side;
* Meeting of the distal and proximal magnet on both sides of the septum, by pulling on the delivery system;
* Release of the distal magnet and activate the retractable wire;
* Insure that wire is not blocked and unblocked it if applicable.

Endoscopy and contrast injection will be performed before and after placement to ensure the correct positioning of the magnets.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient is diagnosed with candy cane syndrome based on clinical and endoscopic and/or radiologic assessment
* Patient has at least one of this 3 symptoms associated to CCS: pain, nausea, vomiting, regurgitation
* Patient agrees and is able to comply with the study procedures and provide written informed consent to participate in the study

Exclusion Criteria

* Refractory stenosis of the UGI proximal to the septum
* Septum height smaller than 2 cm or higher than 8 cm
* Coagulation disorders.

• Previous implantation of a magnetic-sensitive medical device (including active electronic implant, metallic stent, …).
* Dysphagia related to motility disorder
* Planned MRI in the following month (30 days) of intervention
* Condition that could compromise patient safety
* Patient who went through an abdominal surgery less than 8 weeks before implantation of the magnets
* Patient pregnant, breastfeeding or incapacitated
* Patient currently enrolled in another clinical trial
Minimum Eligible Age

18 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Brussel Medical Device Center (BMDC)

UNKNOWN

Sponsor Role collaborator

Erasme University Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Hôpital Universitaire de Bruxelles - Hôpital Erasme

Brussels, , Belgium

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Belgium

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Pauline Van Ouytsel

Role: CONTACT

025556531

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Pauline Van Ouytsel, MSc.

Role: primary

025556531

Secretariat Gastroenterologie Medicale

Role: backup

025553712

References

Explore related publications, articles, or registry entries linked to this study.

Rio-Tinto R, Huberland F, Van Ouytsel P, Delattre C, Dugardeyn S, Cauche N, Delchambre A, Deviere J, Blero D. Magnet and wire remodeling for the treatment of candy cane syndrome: first case series of a new approach (with video). Gastrointest Endosc. 2022 Jun;95(6):1247-1253. doi: 10.1016/j.gie.2021.12.027. Epub 2022 Jan 1.

Reference Type BACKGROUND
PMID: 34979115 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

N2023/021

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Endomina Post RYGB
NCT03675035 COMPLETED NA